What is the role of PARP inhibitors in the treatment of hormone-refractory prostate cancer?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print


Rucaparib, a PARP inhibitor, was approved by the FDA in May 2020 for deleterious BRCA mutation (germline and/or somatic)–associated mCRPC in patients who have been treated with androgen receptor–directed therapy and taxane-based chemotherapy. Accelerated approval was based on an objective response rate (ORR) of 44% in the multicenter, single-arm TRITON2 clinical trial. The confirmatory TRITON3 trial is ongoing. [52]   

Another PARP inhibitor, olaparib, was approved in May 2020 for deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated mCRPC in patients who had progressed following treatment with enzalutamide or abiraterone. Approval was supported by the PROfound phase 3 clinical trial, in which olaparib reduced risk of disease progression or death by 66% (HR 0.34, P < 0.0001) compared with abiraterone or enzalutamide. [53]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!